|Salary:||100% of UK/EU tuition fees paid and an annual stipend for UK residents only (living expenses), currently at £14,553|
|Placed On:||9th April 2019|
|Closes:||31st May 2019|
Value / what is covered?
100% of UK/EU tuition fees paid and an annual stipend for UK residents only (living expenses), currently at £14,553
Awarding body DFE
Number of studentships 1
Summary descriptive text / Example of research project
Long-term respiratory infections can develop in people with conditions such as cystic fibrosis, chronic obstructive pulmonary disease and bronchiectasis and can cause significant morbidity and worse clinical trajectory. Therefore, management of these conditions may include the use of antibiotics chronically for suppression of infection or acutely to treat symptom flare-ups known as exacerbations. However, multi-drug resistant bacteria can emerge during repeated and prolonged use of antibiotics, which is not only a serious worry for patient management but a global health concern. Furthermore, the respiratory microenvironment in chronic infections may affect the ability of bacteria to persist in the presence of antibiotic treatment including the availability of oxygen, pH, ionic conditions and biofilm formation.
It is well recognised that there is an unmet need for the development of new antibiotics or combination of antibiotics that possess activity against increasingly resistant bacteria. However, an alternative to developing new antibiotics is to repurpose approved drugs for new indications. This is an appealing approach as the safety profile of these drugs has already been determined in clinical trials. This research project will:
(1) Screen a selection of compounds alone and in combination for antibiotic activity against a panel of respiratory bacterial pathogens under various experimental conditions which mimic in vivo respiratory conditions
(2) Aim to elucidate mechanisms of action
(3) Determine if candidate compounds induce cross-resistance to currently used antibiotics.
A large collection of clinical isolates is held in the Halo Research Group Biobank and were isolated previously from samples including sputum and bronchoalveolar lavage fluid from adult and paediatric patients and are available for this research project.
Supervisor(s) Dr Laura Sherrard, Prof Michael Tunney
Eligibility / residence Status UK/EU only
Country Northern Ireland
Start date and duration 1st October 2019
Funding covers a three-year full-time PhD.
Research centre/ School Pharmacy
Subject area Pharmacy, microbiology, molecular biology
Candidate requirements / Key skills required for the post
Applicants should have a 1st or 2.1 honours degree (or equivalent) in a relevant subject. Relevant subjects include Pharmacy, Molecular Biology, Pharmaceutical Sciences, Biochemistry, Biological/Biomedical Sciences, Chemistry, Engineering, or a closely related discipline. Students who have a 2.2 honours degree and a Master’s degree may also be considered, but the School reserves the right to shortlist for interview only those applicants who have demonstrated high academic attainment to date
Deadline for applications 31st May 2019
How to apply / contacts
Postgraduate Research applicants for Pharmacy who are interested in applying for a fully funded DFE studentship must have applied to Queen’s, via the Direct Applications Portal, and submitted all required supporting documents by the closing date, which will be announced later in the Academic year.
Relevant links / more information
Training provided through the research project
The successful applicant will be integrated into the highly collaborative Halo Research Group in the School of Pharmacy. The candidate will benefit from broad training in microbiology, molecular biology and statistical analysis of data. Presentation, writing and interpersonal skills will be developed.
Expected impact activities
Presentations at local, national and international conferences
Publication of scientific papers in peer reviewed journals
Type / Role: